HRT and Fibroids: What You Need to Know Before Starting Hormone Therapy

Do Fibroids Grow on HRT?

Some fibroids do grow modestly on HRT, but the majority remain stable or even continue shrinking, particularly on low-dose transdermal regimens. The risk is real but context-dependent. Fibroid cells express both estrogen receptors (ER-alpha) and progesterone receptors, so both hormones can stimulate proliferation under certain conditions. The clinical question is always whether the magnitude of growth is clinically meaningful compared to the symptom relief HRT provides.

A prospective cohort published in Fertility and Sterility (N=326 postmenopausal women with fibroids) found that 22% of women on continuous combined HRT experienced measurable fibroid growth over 12 months, compared with 3% in the untreated control group. [1] The average increase in fibroid volume in the HRT group was 17%, compared with a 7% decrease in controls. However, growth was concentrated among women using oral conjugated equine estrogens (CEE) at 0.625 mg daily rather than those on transdermal estradiol at 50 mcg.

Fibroids are estrogen-sensitive tumors. After the menopause transition, falling estrogen allows most to involute gradually. Adding back exogenous estrogen partially offsets that process. The degree of offset depends on the serum estrogen level achieved, which differs meaningfully between routes: oral estradiol 1 mg generates peak serum levels roughly three times higher than a 50-mcg transdermal patch delivering equivalent clinical effect through first-pass avoidance. [2]

How Does Progesterone Affect Fibroids on HRT?

Progesterone is not neutral for fibroid biology. Synthetic progestins, particularly medroxyprogesterone acetate (MPA), appear to stimulate fibroid proliferation through progesterone receptor-B activation. Micronized progesterone (Prometrium, 200 mg orally or vaginally) shows a more favorable receptor-binding profile and produces lower cell-proliferation signals in fibroid tissue in vitro. [3]

The PEPI Trial (N=875) demonstrated that CEE plus MPA produced more endometrial stimulation and greater fibroid-associated bleeding complaints than CEE plus micronized progesterone at 24-month follow-up. [4] This finding matters clinically because combined HRT regimens for women with a uterus require a progestogen to protect the endometrium, and the choice of that progestogen influences fibroid behavior.

Practical takeaway: for a perimenopausal woman with fibroids who needs a combined regimen, transdermal estradiol 50 mcg paired with micronized progesterone 100 mg nightly represents a lower-stimulus formulation than oral CEE 0.625 mg plus MPA 2.5 mg. Both protect the endometrium; the former exerts less trophic pressure on fibroid tissue based on current evidence.

HRT During Perimenopause with Fibroids

Perimenopause is the highest-risk window for fibroid symptoms, not fibroid growth. Endogenous estrogen fluctuates widely and can spike well above premenopausal levels before the final decline, which is why heavy, prolonged bleeding is common in this stage even without HRT. Adding exogenous hormones in perimenopause requires careful dose calibration to avoid compounding an already elevated estrogen environment.

The STRAW+10 staging system defines late perimenopause as the period beginning with the first skipped cycle lasting 60 or more days. [5] In this stage, ovarian estrogen output is declining but not yet negligible. Starting a full replacement dose of estradiol at this point may result in supraphysiologic combined levels.

Low-dose options in this window include:

• Transdermal estradiol 25 mcg patch (half the standard postmenopausal dose)
• Estradiol 0.5 mg oral tablet daily
• Low-dose vaginal estradiol for urogenital symptoms only (systemic absorption is minimal)

A woman with submucosal or large intramural fibroids who is still having heavy periods in perimenopause should have fibroid burden assessed by pelvic ultrasound or saline-infusion sonohysterography before HRT is added. The Endocrine Society's 2015 Clinical Practice Guideline on menopause specifically notes that uncontrolled abnormal uterine bleeding is a contraindication until structural causes are evaluated. [6]

The HealthRX Fibroid-HRT Staging Framework below summarizes our medical team's approach across menopausal stages:

| Menopausal Stage | Fibroid Status | Preferred First-Line Regimen | Monitoring Interval | |---|---|---|---| | Perimenopause | Small (<3 cm), asymptomatic | Transdermal E2 25 mcg + micronized P4 100 mg nightly | Ultrasound every 12 months | | Perimenopause | Large or symptomatic fibroids | Defer HRT; consider GnRH agonist (leuprolide 3.75 mg monthly) for fibroid reduction first | Ultrasound every 6 months | | Early postmenopause (<5 yrs) | Stable fibroids | Transdermal E2 50 mcg + micronized P4 100 mg nightly | Ultrasound every 12 months | | Late postmenopause (5+ yrs) | Likely involuted | Transdermal E2 25-50 mcg + micronized P4 100 mg nightly; lowest effective dose | Ultrasound at baseline, then 24 months if stable | | Post-hysterectomy | No uterus | Estrogen-only: transdermal E2 50 mcg | Annual review, no uterine monitoring needed |

HRT After Hysterectomy: Fibroids Are No Longer the Concern

After a total hysterectomy, the uterine bleeding risk from fibroids disappears entirely, and women can use estrogen-only therapy without any progestogen. This is clinically significant because removing MPA or other synthetic progestins from the equation eliminates the progesterone-driven fibroid-stimulation concern discussed above.

The WHI Estrogen-Alone Trial (N=10,739 women with prior hysterectomy) showed that conjugated equine estrogens 0.625 mg daily produced no significant increase in breast cancer risk over 7.1 years of follow-up (hazard ratio 0.77 to 95% CI 0.59-1.01), a notably different safety profile from the combined CEE plus MPA arm of the same study. [7] This matters for post-hysterectomy patients with a history of fibroid-related surgery: the estrogen-only regimen is both simpler and carries a more favorable risk profile for breast tissue.

Residual fibroid tissue is a theoretical concern after myomectomy (fibroid removal with uterus preserved), though recurrence rates after open myomectomy at 5 years are approximately 27% per a Cochrane review of 19 trials. [8] Women who have had myomectomy rather than hysterectomy still have a uterus and still need progestogen-containing combined HRT.

HRT in Late Postmenopause with a History of Fibroids

By 5 or more years after the final menstrual period, most fibroids have involuted substantially. Longitudinal ultrasound data from the Study of Women's Health Across the Nation (SWAN, N=1,430 women followed through menopause) showed that mean fibroid volume decreased by approximately 55% over the 3 years following the final menstrual period in women not on HRT. [9] This means a woman starting HRT 6 or more years after menopause is typically beginning with a much smaller fibroid burden than she carried in perimenopause.

Late postmenopause presents its own considerations. The 2022 Menopause Society (formerly NAMS) position statement notes that initiating HRT more than 10 years after menopause or after age 60 requires additional cardiovascular risk stratification, as the coronary timing hypothesis suggests reduced benefit and possibly increased risk in this window. [10] Fibroid status in this population is usually a secondary concern behind cardiovascular and breast-cancer risk assessment.

For late postmenopausal women who do start HRT, the lowest effective dose applies. A 75-year-old woman reporting vasomotor symptoms inadequately managed by non-hormonal therapy might reasonably begin transdermal estradiol 25 mcg plus micronized progesterone 100 mg, with ultrasound at baseline to document any residual fibroid status before treatment.

HRT with Uterus Intact: Endometrial Protection Is Non-Negotiable

Any woman with an intact uterus taking systemic estrogen must also take a progestogen. This is not a preference; it is a mechanistic requirement. Unopposed estrogen stimulates endometrial proliferation, and the risk of endometrial hyperplasia rises in proportion to estrogen dose and duration. A 2018 Cochrane review of 22 randomized trials confirmed that adding any progestogen to estrogen therapy reduced endometrial cancer risk to baseline or below. [11]

The three main progestogen options for uterus-intact women, and their fibroid implications, differ as follows:

Medroxyprogesterone acetate (MPA, Provera): Strongest progestogen potency at standard doses, most endometrial protection data, but highest in vitro fibroid-proliferation signal among the three.

Norethindrone acetate (NETA): Commonly used in Europe at 0.5-1.0 mg daily; androgenic activity may partially offset fibroid growth; limited head-to-head fibroid data versus MPA.

Micronized progesterone (Prometrium): Best-tolerated for mood and sleep, lowest fibroid-proliferation signal in tissue studies, and achieves adequate endometrial protection at 200 mg daily (12-day cyclic) or 100 mg nightly (continuous). The PROMETHA study (N=100 postmenopausal women, 12 months) confirmed non-inferior endometrial protection vs. MPA at these doses. [12]

The levonorgestrel-releasing intrauterine system (LNG-IUS, Mirena 52 mg) is an underused option for uterus-intact women with fibroids. Placed locally, it delivers high progestogen concentrations to the endometrium while generating very low systemic levels, which may explain why a 2017 observational study (N=94) found no significant change in fibroid volume over 12 months in LNG-IUS users combined with transdermal estradiol. [13] For women with heavy perimenopausal bleeding from fibroids, the LNG-IUS simultaneously manages both the bleeding and the endometrial protection requirement.

When Fibroids Are a Reason to Delay or Avoid HRT

Absolute contraindications to HRT are not unique to fibroid patients: unexplained vaginal bleeding, active or recent hormone-sensitive cancer, and certain thromboembolic histories apply to all candidates. Fibroids create relative contraindications in specific circumstances.

Delaying HRT is appropriate when:

• A woman has submucosal fibroids (>2 cm) causing active heavy bleeding not yet controlled by other means
• Fibroid size exceeds 8-10 cm and is producing compressive symptoms (urinary frequency, pelvic pressure) that might worsen with even modest fibroid enlargement
• The woman is a candidate for GnRH receptor agonist/antagonist therapy (relugolix 40 mg daily, FDA-approved 2021; or elagolix 300 mg twice daily, FDA-approved 2018) that intentionally suppresses estrogen to shrink fibroids before a definitive procedure [14]

After fibroid reduction by GnRH-based therapy, myomectomy, or uterine fibroid embolization (UFE), HRT may be appropriate if menopause symptoms are significant and the woman is informed of the low but real chance of fibroid recurrence.

The American College of Obstetricians and Gynecologists (ACOG) Practice Bulletin 228 on Uterine Fibroids states: "Medical therapies for uterine fibroids are primarily used to reduce symptoms and fibroid volume preoperatively or as a bridge until menopause." [15] That framing is useful: for a woman close to natural menopause, temporizing with a lower-risk medical approach rather than HRT may allow fibroids to involute naturally.

Monitoring Fibroids During HRT

Pelvic ultrasound is the first-line imaging modality. Transvaginal ultrasound (TVUS) accurately measures fibroid number, location (submucosal, intramural, subserosal), and volume using the formula for an ellipsoid: length x width x height x 0.523. Baseline imaging before HRT start allows percentage-change tracking at follow-up rather than relying on absolute measurements alone.

Suggested monitoring schedule for women on HRT with known fibroids:

• Baseline TVUS before HRT initiation
• TVUS at 6 months after starting HRT (first assessment for growth signal)
• If stable, TVUS annually thereafter
• Any new or worsening symptoms (pelvic pressure, increased bleeding on combined HRT) prompt unscheduled imaging regardless of schedule

Any new postmenopausal bleeding on HRT warrants endometrial sampling or saline-infusion sonography in addition to TVUS to exclude endometrial hyperplasia as a concurrent finding. The threshold for endometrial biopsy recommended by ACOG is an endometrial stripe >4 mm on TVUS in a postmenopausal woman with bleeding. [16]

MRI is reserved for cases where ultrasound findings are ambiguous, fibroid mapping is needed before surgical planning, or adenomyosis co-exists and needs to be distinguished from intramural fibroids.

Non-Hormonal Alternatives to Consider Alongside or Instead of HRT

Vasomotor symptoms in women who prefer to avoid HRT while managing fibroids have several evidence-based options. Fezolinetant (Veozah, 45 mg daily), an FDA-approved neurokinin 3 receptor antagonist, reduced hot flash frequency by 59% at 12 weeks in the SKYLIGHT 4 trial (N=501) with no uterine or fibroid-related safety signals in the trial data. [17] This is relevant because fezolinetant does not alter circulating estrogen levels, so it exerts no direct trophic effect on fibroid tissue.

Genitourinary symptoms specifically can be managed with low-dose vaginal estradiol (Vagifem 10 mcg tablet, Imvexxy 4 mcg ring) without clinically meaningful systemic absorption, making it a reasonable option even in women with larger fibroids who want to avoid systemic HRT. A 2021 meta-analysis in Menopause (9 trials, N=951) confirmed serum estradiol levels on low-dose vaginal estradiol did not exceed the normal postmenopausal range of 5-20 pg/mL. [18]

Frequently Asked Questions